Sugi Predict

Sugi Predict / Compounds / SCHEMBL5020955

SCHEMBL5020955

SCHEMBL5020955

Cc1noc(C)c1S(C)(=O)=O

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.49
▸ MAPT P10636 2/20 0.47
▸ MAPK1 P28482 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.42
▸ TSHR P16473 2/20 0.42
▸ GAA P10253 3/20 0.41
▸ HTT P42858 1/20 0.41
▸ NR3C1 P04150 2/20 0.41
▸ PGR P06401 1/20 0.41
▸ NR3C2 P08235 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ CHRM4 P08173 1/20 0.39
▸ LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL51166 0.79 CA12 (0.48) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL103900 0.79 KMT2A (0.47) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL2652292 0.79 KMT2A (0.47) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL1323519 0.79 KMT2A (0.47) KMT2AMAPTMAPK1ALDH1A1TSHR
Hydrochloric Acid SCHEMBL27328972 0.77 KMT2A (0.46) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL12922883 0.77 KMT2A (0.46) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL7038803 0.77 KMT2A (0.46) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL12895708 0.76 KMT2A (0.45) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL8187791 0.76 MAPT (0.60) KMT2AMAPTMAPK1ALDH1A1TSHR
SCHEMBL8354304 0.76 KMT2A (0.57) KMT2AMAPTALDH1A1TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059010-A1 COMPOUNDS FOR TREATING CANCER GENESIS THERAPEUTICS, INC. (US) 2024-03-21 — — WO disclosed
US-9856254-B2 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-01-02 — — US disclosed
US-9790169-B2 IDO inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-10-17 — — US disclosed
US-20170231999-A1 IDO INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-17 — — US disclosed
US-9598411-B2 Substituted benzimidazole-type piperidine compounds and uses thereof PURDUE PHARMA L.P. (US) 2017-03-21 — — US disclosed
US-20160289171-A1 IDO INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2016-10-06 — — US disclosed
US-20160280707-A1 ALKOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2016-09-29 — — US disclosed
US-20160280707-A1 ALKOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2016-09-29 — — US disclosed
US-9365567-B2 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2016-06-14 — — US disclosed
US-9365567-B2 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2016-06-14 — — US disclosed
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2007-06-21 — — US disclosed
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2007-06-21 — — US disclosed
US-7214698-B2 Beta-agonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-05-08 — — US disclosed
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 — — US disclosed
US-20070060754-A1 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2007-03-15 — — US disclosed
US-20070060754-A1 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2007-03-15 — — US disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 — — US disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 — — US disclosed
US-7176214-B2 Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-13 — — US disclosed
WO-2004103998-A1 QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060754-A1 Alkoxy substituted imidazoquinolines IL2, IFNG, IRF3 KMT2A 2789/4885MAPT 4571/4885MAPK1 2511/4885
US-20170231999-A1 IDO INHIBITORS IDO1, IDO2, INMT KMT2A 461/4885MAPT 1988/4885MAPK1 1890/4885
US-20160280707-A1 ALKOXY SUBSTITUTED IMIDAZOQUINOLINES IL2, IFNG, IRF3 KMT2A 2789/4885MAPT 4571/4885MAPK1 2511/4885
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma MAPK1, MAPK3, MAPK4 KMT2A 1449/4885MAPT 3082/4885MAPK1 1/4885
US-20160289171-A1 IDO INHIBITORS IDO1, IDO2, INMT KMT2A 461/4885MAPT 1988/4885MAPK1 1890/4885
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A KMT2A 2592/4885MAPT 4279/4885MAPK1 2233/4885
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A KMT2A 2592/4885MAPT 4279/4885MAPK1 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.